$32.37
0.74%
Nasdaq, Sep 19, 10:12 pm CET
ISIN
US88322Q1085
Symbol
TGTX

TG Therapeutics, Inc. Stock price

$32.37
+4.45 15.94% 1M
-10.10 23.78% 6M
+2.27 7.54% YTD
+7.09 28.05% 1Y
+25.64 380.98% 3Y
+6.89 27.04% 5Y
+19.91 159.79% 10Y
-3,848.88 99.17% 20Y
Nasdaq, Closing price Fri, Sep 19 2025
-0.24 0.74%
ISIN
US88322Q1085
Symbol
TGTX
Industry

Key metrics

Basic
Market capitalization
$5.1b
Enterprise Value
$5.1b
Net debt
positive
Cash
$251.9m
Shares outstanding
158.0m
Valuation (TTM | estimate)
P/E
87.5 | 40.5
P/S
11.3 | 8.6
EV/Sales
11.3 | 8.5
EV/FCF
negative
P/B
18.6
Financial Health
Equity Ratio
38.5%
Return on Equity
10.5%
ROCE
16.2%
ROIC
27.0%
Debt/Equity
0.9
Financials (TTM | estimate)
Revenue
$454.1m | $600.7m
EBITDA
$85.9m | $149.5m
EBIT
$85.8m | $149.9m
Net Income
$60.5m | $126.3m
Free Cash Flow
$-59.2m
Growth (TTM | estimate)
Revenue
31.0% | 82.6%
EBITDA
-15.8% | 256.1%
EBIT
-15.7% | 257.5%
Net Income
-36.8% | 440.1%
Free Cash Flow
-187.4%
Margin (TTM | estimate)
Gross
87.0%
EBITDA
18.9% | 24.9%
EBIT
18.9%
Net
13.3% | 21.0%
Free Cash Flow
-13.1%
More
EPS
$0.4
FCF per Share
$-0.4
Short interest
20.2%
Employees
338
Rev per Employee
$970.0k
Show more

Is TG Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

TG Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a TG Therapeutics, Inc. forecast:

12x Buy
80%
2x Hold
13%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a TG Therapeutics, Inc. forecast:

Buy
80%
Hold
13%
Sell
7%

Financial data from TG Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
454 454
31% 31%
100%
- Direct Costs 59 59
136% 136%
13%
395 395
23% 23%
87%
- Selling and Administrative Expenses 187 187
36% 36%
41%
- Research and Development Expense 122 122
48% 48%
27%
86 86
16% 16%
19%
- Depreciation and Amortization 0.04 0.04
75% 75%
0%
EBIT (Operating Income) EBIT 86 86
16% 16%
19%
Net Profit 60 60
37% 37%
13%

In millions USD.

Don't miss a Thing! We will send you all news about TG Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TG Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 - 26, 2025 in Barcelo...
Neutral
GlobeNewsWire
14 days ago
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the company's anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS).
Neutral
Seeking Alpha
18 days ago
TG Therapeutics, Inc. (NASDAQ:TGTX ) Cantor Global Healthcare Conference 2025 September 3, 2025 10:20 AM EDT Company Participants Michael Weiss - Chairman, CEO & President Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Welcome, everyone, to day 1 of Cantor's Global Healthcare Conference.
More TG Therapeutics, Inc. News

Company Profile

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Head office United States
CEO Michael Weiss
Employees 338
Founded 1993
Website www.tgtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today